Innovators and generics, neither are wholly satisfied with the current Canadian system of intellectual property and related rights (IPRs). Ongoing trade negotiations between Canada and the European Union has fuelled the debate over effective IPR for innovative pharmaceutical products.
Read the full article, written by Steven Garland and Daphne Lainson of our Ottawa office, which appeared in the August 2012 issue of Intellectual Property Magazine.